[go: up one dir, main page]

GB2038181A - Galenical compositions - Google Patents

Galenical compositions Download PDF

Info

Publication number
GB2038181A
GB2038181A GB7943633A GB7943633A GB2038181A GB 2038181 A GB2038181 A GB 2038181A GB 7943633 A GB7943633 A GB 7943633A GB 7943633 A GB7943633 A GB 7943633A GB 2038181 A GB2038181 A GB 2038181A
Authority
GB
United Kingdom
Prior art keywords
composition according
enteric
coating
sterol
ergot alkaloid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
GB7943633A
Other versions
GB2038181B (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sandoz AG
Original Assignee
Sandoz AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz AG filed Critical Sandoz AG
Publication of GB2038181A publication Critical patent/GB2038181A/en
Application granted granted Critical
Publication of GB2038181B publication Critical patent/GB2038181B/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The preparations for oral application comprise a coating resistant to gastric juice and a core comprise of an ergot alkaloid and of a sterile ester. The preparations are characterized by an improved and enhanced release of the active principle and a higher efficiency. The core may be comprised of a solid solution of the ergot alkaloid. The coating resistant to the gastric juice may be covered with an outer layer of the active principle.

Description

SPECIFICATION Galenical compositions The invention provides a galenicai compositions for oral application of ergot alkaloids which are characterised by a prolonged effect and a good bioavailability of the active agent.
It is undisputed amongst medicinal specialists, that under many circumstances it is preferred to apply a drug once a day instead of more times a day.
This may be achieved in so-called "retard systems" by retarding and delaying the release of the active agent, with the aim of producing a longer duration of the therapeutic effect. In the field of the ergot therapy, a retardation with classical systems, e.g.
with a matrix system or with the aid of microencapsulation, induces each time an important decrease of the total bioavailability.
It is also known, that ergot alkaloids are stable in the presence of acids, which means that they do not disintegrate in the gastric sluices, and that the resorption of ergot alkaloids takes place mainly in the intestinal tract. Enteric coated drugs containing an ergot alkaloid are therefore not expected to provide an improved bioavailability.
It is therefore surprising that with the aid of an enteric coating one observes that the duration of action of an ergot alkaloid is not only significantly prolonged but that, moreover, the total bioavailability is notably improved when the coated core contains, in addition to the ergot alkaloid, a polyalkoxyalkylene sterol ether.
The invention therefore provides, more specifiwally, a solid enteric-coated composition for oral application, the core of the composition containing an ergot alkaloid and a polyalkoxyalkylene sterol either.
The invention also provides a process for the production of compositions according to the invention, by enteric coating a core comprising an ergot alkaloid and a polyalkoxyalkylene sterol ether hereinafter designated sterol ether).
The term "core" comprises any mixture of an srgot alkaloid and a sterol ether, if desired in admixture with further physiologically acceptable material, that can be surrounded by a enteric-coating. The term "core" comprises, in a wide sense, not only tablets, pellets or granules but also capsules, e.g.
soft or hard gelatine capsules filled with a liquid or Naxy mixture of an ergot alkaloid, a sterol ether and optionally pharmaceutically acceptable material.
Such capsules may then be enteric-coated, e.g. in conventional manner. When tablet cores are used they have preferably a hardness of from ca 10 to ca 70N.
The pellets or granules may, after application of the enteric-coating, be used as such or to fill capsules, e.g. hard gelatine capsules. Suitable applications of the compositions according to the invention are therefore tablets, pellets, granules or capsules.
The term "ergot alkaloids" comprises natural ergot alkaloids such as ergotamine, ergocristine, x-ergocryptine, P-ergocryptine and ergocornine, synthetic or semi-synthetic derivatives thereof such as ergovaline, dihydroergotoxine (also known as co-dergocrine) and dihydroergotamine in free base form or in the form of an acid addition salt with pharmaceutically acceptable organic or inorganic acids such as methanesuphonic, maleic, tartaric or hydrochloric acid.
The acitve agents which are of special interest for use in the invention, are compounds of formula I
wherein B1 is hydrogen or halogen, R2 is hydrogen or Cl-4 alkyl, B3 is isopropyl, sec. -butyl, isobutyl or benzyl, R4 is methyl, ethyl or isopropyl, and either Rs is hydrogen and R6 is hydrogen or methoxy or B5 and R6 together are an additional bond, or mixtures thereof.
When R1 is halogen, it is preferably bromine.
Especially preferred compositions of the invention contain dihydroergotoxine, bromocryptine or dihydroergotamine in free base form or, preferably, in acid addition salt form as active agent.
Preferred sterol ethers for use in the compositions of the invention have a hydrophilic-lipophilic balance value (HLB group number) of from about 10 to about 20, especially from 12 to 16. They preferably are ethers of lanosterol, dihydrocholesterine and, particularly, of cholesterine or mixtures of such ethers. Especially suitable sterol ethers are sterols etherified with an average of 8 to 75, preferably 9 to 30 alkylene oxide units. The hydroxy group in the end alkylene unit of such sterol ethers may be partially or completely acylated, e.g. by acyl radicals of aliphatic carboxylic acids, such as acetyl. Especially preferred are sterol ethers etherified with ethylene oxide and/or propylene oxide units.
manner by etherifying the sterol with the corresponding amount of epoxide and optionally acylating the so obtained alcohols. They are in general available on the market and are e.g. offered for sale by the firm Amerchol under the trade name Solulan.
Examples of Solulans types which are available on the market and are suitable for use in the compositions according to the invention are such obtainable by alkoxylation of e.g.
a) 1 mol cholesterin with about 24 mol ethylene oxide (Solulans C-24) b) 1 equivalent of lanolinalcohols with about 16 equivalents ethylene oxide (Solulans 16) c) 1 equivalent of lanolinalcohols with about 25 equivalents ethylene oxide (Solulane 25) d) 1 equivalent of lanolinalcohols with about 75 equivalents ethylene oxide (Solulans 16) e) 1 equivalent of lanolinalcohols with about 10 equivalents propylene oxide (Solulan " PB-10) and also the f) partially acetylated derivative of 1 equivalent of lanolinalcohols ethoxylated with about 10 equi valents ethylene oxide (Solulans 98) and the g) completely acetylated derivative of 1 equivalent of lanolinalcohols ethoxylated with about 9 equivalents ethylene oxide (SolulanD 97) The term "about" in the above paragraphs a) to g) indicates that the given number of ethylene oxide or propylene oxide equivalents involved is a mean value, i.e. that some sterol ethers bear more and others less ethyleneoxy- or propyleneoxy-groups.
Lanolinalcohols are also known as wool fat alcohols (Handbuch der Kosmetika und riechstoffe, 2. Ed. 1950, Vol. I, page 1101 (Janistyn)) and are a mixture of i.e. cholesterin, dihydrocholesterin and lanosterol.
The term "enteric coating" comprises any pharmaceutically acceptable coating preventing the release of the active agent in the stomach and sufficiently disintegrating in the intestinal tract (by contact with approximately neutral or alkaline intestine juices) to allow the resorption of the active agent through the walls of the intestinal tract. Various in vitro tests for determining whether or not a coating is classified as an enteric coating have been published in the pharmacopoeia of various countries.
More specifically, the term "enteric coating" according to the invention refers to a coating which remains intact for at least 1 hour, e.g. 2 hours, in contact with artificial gastric juices such as HCI of pH 1.2 at 36 to 38"C and thereafter disintegrates with 30 minutes in artificial intestinal juices such as a KH2PO4 buffered solution of pH 6.8.
The thickness of the coating may vary and dependsinteralla on its permeability in water and acids and the desired retard effect. In general satisfactory results are obtained with a coating of 5-100 ,am, preferably 20-80,am, thickness. The coating is suitably selected from macromolecular polymers.
Suitable polymers are listed in e.g. Hagers Handbuch der pharmazeutischer Praxis, 4th Ed. Vol. 7a, pages 739 to 742 and 776 to 778, (Springer Verlag, 1971) and Remington's Pharmaceutical Sciences, 13th Ed., pages 1689 to 1691 (MackPubl. Co., 1970) and comprise e.g. cellulose ester derivatives, cellulose ethers, acrylic resins, such as methylacrylate copolymers and copolymers of maleic acid and phthalic acid derivatives.
The preferred films are made from cellulose acetate phthalate; copolymers derived from methylacrylic acid and esters thereof, containing at least 40% methylacrylic acid; and especially hydroxypropyl methylcellulose phthalate. An example of an appropriate cellulose acetate phthalate is the marketed product CAP (Eastman Kodak, Rochester N.Y., USA). Examples of suitable hydroxypropyl methyl cellulose phthalates are the marketed products HP 50 and HP 55 (Shinetsu, Tokyo, Japan).
EXAMPLE 1 Tablet cores consisting of 3 g dihydroergotamine, 75 g cholesterin which is ethoxylated with about 24 ml ethylene oxide (Solulans (C-24)) and 229 disperse silicagel are heated to 30 during 10 minutes with the aid of warm air of 50" in a coating pan which is repeatedly rotated. The tablet cores are then sprayed, with the aid of a spray pistol, with a solution of 5.4 g hydroxypropyl methylcellulose phthalate (HP50) and 1.35 g di-n-butylphthalate in a 1:1 ethanol/acetone mixture, at a spray pressure of 1-1.5 bar using conventional interval spray coating procedures, and the so obtained coated tablets are then dried.
EXAMPLE2 One proceeds analogous to Example 1, uses, however, 75 g lanolin alcohols ethoxylated with about 25 equivalents ethylene oxide (Solulane 25) instead of 75 9 cholesterin ethoxylated with about 24 mol ethylene oxide.
EXAMPLE 3-Coated tablets with cores in solid sol ution form 15 g Dihydroergotoxine methanesulphonate, 1.05 g (SolulanD C-24), 33.95 g polyvinylpyrrolidone (average molecular weight 25,000) and 250 ml methanol are charged into a 1 litre round-bottomed flask. The flask is attached to a rotary evaporator and rotated at a bath temperature of 60 until the flask contents reach 60 , by which time a clear solution is obtained.
The bath temperature is maintained at 60 and the solvent evaporated under reduced pressure until the residue has a syrupy consistency. The residue is decanted into an evaporating basin and left to solidify for 2 hours at room temperature.
The solid residue is dried in a vacuum oven at 30 , ca. 1 Torrfor ca. 12 hours, ground to a fine powder and dried again.
26.8 g of the so obtained solid solution are then mixed with the following adjuvants: silicium dioxide 1.0 g (Aerosil" 200, Degussa) polyvinylpyrrolidone 8.0 g (crosslinked) corn starch 20.0 g Talc 30.0 g Solulane C-24 30.0 g cellulose granules 42.0 g (Elcema G 250) lactose 122.0 g until an homogenous mixture is obtained and then pressed, in conventional manner, to tablet cores of 140.0 mg (hardness 10-32N).
The so obtained cores are then, analogous to Example 1, sprayed with a solution of cellulose acetate phthalate (CAP) 90.0 g di-n-butylphthalate 225 g acetone 240.0 9 ethanol 21.0 9 dichloromethane 526.5 g 900.0 g until the cores are coated with ca. 10 mg of the cellulose acetate phthalate/di-n-butylphthalate mixture per core.
The so obtained coated tablets are resistant against the gastric juices since the cores remain intact after a treatment of 1 hour with artificial gastric juices of pH = 1.2. The disintegration time in artificial intestine juices is atpH 5.5 longerthan 1 hour, and lies at pH 6.0 between 23-28 minutes and at pH 6.8 between 12 and 16 minutes.
EXAMPLE 4 One proceeds analogous to Example 3, spraying, however, the tablet cores of 140 mg with a solution of 140.0 g hydroxypropyl methylcellulose phthalate (HP 50) and 28 9 di-n-butylphthalate in a mixture of 616 g ethanol and 616 g acetone, until the cores are coated with ca. 9 mg of the hydroxypropyl methylcellulose phthalate/di-n-butylphthalate mixture (ratio 10:2) per core.
EXAMPLE 5 Analogous to Example 3 is obtained a solid solution of 4 g dihydroergotoxine methanesulphonate, 0.3 g Solulan16 and 9.1 g polyvinylpyrrolidone (average mol weight 2000).
This solid solution is then mixed with silicion dioxide 0.5 g polyvinylpyrrolidone 4.0 9 (average mol weight 2000) corn starch 10.0 talc 15.0 9 Solulan16 15.0 g cellulose granules 21.0 g (Elcema G 250) lactose 61.1 9 and this mixture pressed to tablets of 140.0 mg.
The so obtained tablet cores are then sprayed, analogous to Example 4, until each core is coated either with ca 10 mg or with ca 15 mg of the mixture: hydroxypropyl methylcellu lose phtha late/di-nbutylphthalate.
Analogous to the procedure described in the above Examples are obtained the tablets as listed below in Table In cases Ib and Ic (see table) are used, the tablet cores are in solid solution form.
EXAMPLE 6 7 8 9 10 11 12 13 la Dihydroergot- 4.0 4.0 4.0 4.0 4.0 4.0 la Dihydroergot- 4.0 4.0 4.0 4.0 4.0 4.0 oxinemesylate Dihydroergot Ib Solulan C24 0.3 0.3 0.3 0.3 0.3 Ic Polyvinyl pyrrolidone 9.1 9.1 9.1 9.1 9.1 11 Solulans C24 15.0 15.0 31.7 7.3 23.7 15.3 22.9 22.
Silicion dioxide 2.4 2.4 0.5 0.5 0.5 0.5 3.6 3.
corn starch 24.0 24.0 10.0 10.0 10.0 10.0 36.0 36.
Cellulose 72.0 72.0 21.0 21.0 21.0 21.0 108.0 108.
lactose 110.8 110.8 44.4 68.8 52.4 61.1 166.4 166.
Magnesium stearate 2.4 2.4 Kollidon CE 5050 4.0 4.0 4.0 4.0 Polyvinyl pyrolidone (25) 9.1 13.5 talc 15.0 15.0 15.0 HPMCP* 26.0 7.0 7.2 9.0 9.0 9.0 7.2 7.2 Di-n-butylphthalate 1.8 - - - 1.8 1.
(1) (1) total weight (mg) - 266.0 247.0 149.0 149.0 149.0 149.0 369.0 369.
* HPMCP = Hydroxypropyl methylcellulose phthalate (1) the cores of these tablets were pressed to possess a hardness of 50-60N EXAMPLE 14: Tablet with an outer medicament layer (Mantle tablet) 3) The cores are prepared analogous to Example 3 vy mixing 26.8 9 of a solid solution (consisting of 8.0 3 dihydroergotamine mesylate, 0.6 g Solulane C-24 and 18.2 g polyvinylpyrrolidone) together with 1.0 g highly disperse silicagel, 8.0 9 crosslinked polyvinyl- zyrrolidone,20 g corn starch, 47.4 g Solulane C-24, T2.0 g cellulose granules, 104.8 g lactose and 30.0 g :alc until the mixture is homogenous. The mixture is hen pressed to cores of 140.0 mg.
z) The so obtained cores are sprayed with a soluion of 140.0 9 hydroxypropyl methylcellulose phthaate and 28.0 9 di-n-butylphthalate in a mixture of 316 9 ethanol and 616 9 acetone, until the cores are :oatedwith ca. 10 mg per tablet.
c) The outer medicament layer is prepared by mixing 4.0 g dihydroergotamine mesylate with 4.0 g disperse silica-gel, 6.0 g magnesium stearate, 166.8 g cellulose powder, 40.0 gtalc, 191.2 9 corn starch and 348.0 9 calcium hydrogen phosphate until the mixture is homogenous. This mixture is then pressed with the coated tablets (according to Example 14b) to prepare tablets with an outer medicament layer, having a total weight of 530.0 mg per tablet.
EXAMPLE 15 One proceeds analogous to any one of Examples 1 to 14, using 4 mg bromocryptine, 4 mg dihydroergovaline or4 mg dihydroergonine instead of dihydroergotoxine or dihydroergotamine, and obtains tablets containing the corresponding ergot alkaloid as active agent.
EXAMPLE 16: Clinical trial The composition according to Example 4 was compared with a solid solution of dihydroergotoxine mesylate (composition A) and a conventional composition of dihydroergotoxine mesylate (composition B).
Each person treated obtained 4 mg dihydroergotoxine mesylate.
The result is listed in the following table.
Composition Example A B Concentration in Plasma after 20' 0.0470.012 0.376i0.078 0.215 +0.064 40' 0.092 +0.039 0.472+0.070 0.506+0.049 Max. conc. in O.615i0.077 0.507+0.071 0.538+0.037 plasma (ng.ml-') Time (in hours) 3.33+0.48 0.64+0.06 0.78+0.12 after which max.
is reached Bioavailability AUC (0-24 hours) 4.778+0.415 3.875+0.279 ' 3.754+0.171 (ng, ml-t) % eliminated by 1.010+0.154 0.787+0.121 0.740+0.081 urine (0.96 hours) The good retarding effect and the excellent bioavailability of the composition according to the invention is clearly illustrated by the figures in the above table. On the other hand, we found a clearly inferior bioavailability (60-70% of composition B) when testing a marketed composition of dihydroergotoxin retarded according to conventional manner.
Analogous test with other compositions according to the invention give similar good results. Additionally, a marketed composition of dihydroergotamine retarded according to conventional manner, showed a bioavailability that was about 30 to 40% inferior to that fond with the corresponding unretarded reference composition and inferior to compositions according to the invention.

Claims (32)

1. A solid enteric-coated composition for oral application, the core of the composition containing an ergot alkaloid and a polyalkoxyalkylene sterol ether.
2. A composition according to Claim 1 wherein the ergot alkaloid is a compound of formula
wherein R, is hydrogen or halogen, R2 is hydrogen or C14 alkyl, R3 is isopropyl, sec. -butyl, isobutyl or benzyl, R4 is methyl, ethyl or isopropyl, and either B5 is hydrogen and R6 is hydrogen or methoxy or B5 and R6 together are an additional bond, or mixtures thereof.
3. A composition according to Claim 1 and 2 wherein the ergot alkaloid is dihydroergotamine.
4. A composition according to Claim 1 and 2 wherein the ergot alkaloid is dihydroergotoxine.
5. A composition according to Claim 1 and 2 wherein the ergot alkaloid is bromoergocryptine.
6. Acomposition according to any one of Claims 1 to 5 wherein the polyalkoxyalkylene sterol ether has an hydrophilic-lipophilic balance of from 10 to 20.
7. A composition according to Claim 6 wherein the polyalkoxyalkylene sterol ether has a hydrophilic-lipophilic balance of from 12to 16.
8. A composition according to any one of claims 1 1 to 7 wherein the sterol part of the polyalkoxyal- kylene sterol ether is lanosterol, dihydrocholesterin and/or cholesterin.
9. A composition according to any one of Claims 1 to 8, wherein the polyalkoxyalkylene sterol ether is a a sterol etherified with about 8 to about 75 alkylene oxide units.
10. A composition according to Claim 9, wherein the sterol is etherified with from about 9 to about 30 alkylene units.
11. A composition according to any of Claims 1 to 10 wherein the polyalkoxyalkylene sterol ether, is a sterol etherified with ethylene oxide or propylene oxide.
12. A composition according to any of Claim 1 tp 11 wherein the enteric-coating is selected from a cellulose ester derivative, a cellulose ether, an acrylic resin or a copolymer of maleic acid and phthalic acid derivatives.
13. A composition according to Claim 12 wherein the enteric-coating is of cellulose acetate phthalate.
14. A composition according to Claim 12 wherein the enteric-coating is of hydroxypropyl methylcellulose phthalate
15. A composition according to Claim 12 wherein the enteric-coating is of methylacrylic acid and esters thereof, containing at least 40% methylacrylic acid.
16. A composition according to any one of Claims 1 to 15 wherein the enteric-coating contains a softener.
17. A composition according to Claim 16 wherein the softener is di-n-butylphthalate.
18. A composition according to any one of Claims 1 to 17 in the form of tablets, granules, pellets or capsules.
19. A composition according to Claim 18 in tablet form wherein the tablet additionally has an outer medicament layer surrounding the enteric-coating.
20. A composition according to any one of Claims 1 to 19 wherein the weight ratio ergot alkaloid polyalkoxyalkylene sterol ether is from 1:1 to 1:25.
21. A composition according to Claim 20, wherein the weight ratio ergot alkaloid : polyalkoxyalkylene sterol ether is from 1:2 to 1:8.
22. A composition according to any one of Claims 1 to 21 wherein the core is in solid solution form.
23. A composition according to Claim 22 wherein the core contains a polyalkylene glycol, polyvinylpyrrolidone and/or a copolymer of vinylpyrrolidone and vinyl acetate as solid solvent.
24. A composition according to Claim 23, wherein the weight ratio within the core of ergot alkaloid: polyalkoxyalkylene sterol ether : solid solvent lies in the range 1:1-10:0.1-10.
25. A composition according to Claim 24 wherein the weight ratio lies in the range 1:2-8 : 0.1-10.
26. A composition according to Claim 25 wherein the weight ratio lies in the range 1:2-5 : 0.1-5.
27. A composition according to any one of Claims 22 to 26 wherein the core contains a stabilizer.
28. A composition according to Claim 27, wherein the core is stabilised by adjusting its pH, with an acid, at pH 4-6.
29. Process for the production of a composition as defined in any one of the preceding claims characterised by enteric-coating a core comprising an ergot alkaloid and a polyalkoxyalkylene sterol ether.
30. Process according to Claim 29, wherein the enteric-coating is applied in conventional manner.
31. Process according to Claim 30 for entericcoating tablets, pellets or granules wherein the cores are sprayed with a solution of the enteric-coating.
32. Process according to Claim 31, characterised in that the cores, before spraying, are warmed up at 25 up to 40".
GB7943633A 1978-12-21 1979-12-19 Galenical compositions Expired GB2038181B (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CH1301978 1978-12-21
CH1302178 1978-12-21
CH56779 1979-01-19
CH56679 1979-01-19

Publications (2)

Publication Number Publication Date
GB2038181A true GB2038181A (en) 1980-07-23
GB2038181B GB2038181B (en) 1983-05-11

Family

ID=27427929

Family Applications (1)

Application Number Title Priority Date Filing Date
GB7943633A Expired GB2038181B (en) 1978-12-21 1979-12-19 Galenical compositions

Country Status (23)

Country Link
AT (1) AT372279B (en)
AU (1) AU534051B2 (en)
CA (1) CA1139222A (en)
CH (1) CH642259A5 (en)
CY (1) CY1330A (en)
DE (1) DE2950154A1 (en)
DK (1) DK154607C (en)
FI (1) FI793888A7 (en)
FR (1) FR2444463A1 (en)
GB (1) GB2038181B (en)
HK (1) HK37986A (en)
HU (1) HU182577B (en)
IE (1) IE49323B1 (en)
IL (1) IL59003A (en)
IT (1) IT1164029B (en)
KE (1) KE3617D (en)
MY (1) MY8500129A (en)
NL (1) NL187229C (en)
NZ (1) NZ192457A (en)
PH (1) PH25178A (en)
PT (1) PT70614A (en)
SE (1) SE442265B (en)
WO (1) WO1980001242A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2160100A (en) * 1984-06-14 1985-12-18 Sandoz Ltd Galenical retard formulations
US4562061A (en) * 1981-04-27 1985-12-31 Aktiebolaget Hassle Pharmaceutical preparation
GB2210790A (en) * 1987-09-05 1989-06-21 Chen Li Ji Chinese Medicine Ph Two-layer enteric coated pellet

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4366145A (en) * 1981-06-24 1982-12-28 Sandoz, Inc. Soft gelatin capsule with a liquid ergot alkaloid center fill solution and method of preparation
DE3413955A1 (en) * 1983-04-22 1984-10-25 Sandoz-Patent-GmbH, 7850 Lörrach Pharmaceutical product containing co-dergocrine and a calcium antagonist
HU192050B (en) * 1983-04-22 1987-05-28 Sandoz Ag Process for production of medical preparative containing co-dergocrin and one piridin-dicarbonic acid diesthertype calcium-antagonist
GB8426922D0 (en) * 1984-10-24 1984-11-28 Sandoz Ltd Galenic formulation
AT388101B (en) * 1985-02-05 1989-05-10 Sandoz Ag Process for the production of a pharmaceutical composition for oral administration with controlled release of active ingredient

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3432593A (en) * 1963-09-18 1969-03-11 Key Pharm Inc Delayed and sustained release type pharmaceutical preparation
DE2528257C2 (en) * 1974-07-04 1986-02-13 Sandoz-Patent-GmbH, 7850 Lörrach New galenic preparation
DE2546577B2 (en) * 1975-10-17 1981-04-02 Sandoz-Patent-GmbH, 7850 Lörrach Solid substances made from polyvinylpyrrolidone and ergot alkaloids

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4562061A (en) * 1981-04-27 1985-12-31 Aktiebolaget Hassle Pharmaceutical preparation
GB2160100A (en) * 1984-06-14 1985-12-18 Sandoz Ltd Galenical retard formulations
AT391806B (en) * 1984-06-14 1990-12-10 Sandoz Ag METHOD FOR PRODUCING A SOLID DISPERSION OF A PHARMACOLOGICAL ACTIVE SUBSTANCE IN A POLYMERIC MATRIX
GB2210790A (en) * 1987-09-05 1989-06-21 Chen Li Ji Chinese Medicine Ph Two-layer enteric coated pellet

Also Published As

Publication number Publication date
IE792471L (en) 1980-06-21
DK529879A (en) 1980-06-22
KE3617D (en) 1986-04-18
CY1330A (en) 1986-06-27
CH642259A5 (en) 1984-04-13
NZ192457A (en) 1983-06-17
FI793888A7 (en) 1981-01-01
IT7951153A0 (en) 1979-12-20
PH25178A (en) 1991-03-27
DK154607C (en) 1989-06-05
IL59003A (en) 1982-12-31
AU534051B2 (en) 1984-01-05
AT372279B (en) 1983-09-26
FR2444463B1 (en) 1983-02-25
MY8500129A (en) 1985-12-31
NL187229C (en) 1991-07-16
AU5403179A (en) 1980-06-26
DK154607B (en) 1988-12-05
GB2038181B (en) 1983-05-11
HK37986A (en) 1986-05-30
ATA803679A (en) 1983-02-15
SE7910227L (en) 1980-06-22
NL7909105A (en) 1980-06-24
HU182577B (en) 1984-02-28
IT1164029B (en) 1987-04-08
FR2444463A1 (en) 1980-07-18
SE442265B (en) 1985-12-16
PT70614A (en) 1980-01-01
WO1980001242A1 (en) 1980-06-26
IE49323B1 (en) 1985-09-18
DE2950154C2 (en) 1989-05-11
DE2950154A1 (en) 1980-07-10
CA1139222A (en) 1983-01-11

Similar Documents

Publication Publication Date Title
US5019398A (en) Pharmaceutical composition providing the sustained-release of valproic acid
CA1339072C (en) Pharmaceutical formulation as well as a process for its preparation
EP0202051B1 (en) Therapeutic compositions for oral administration
US4794001A (en) Formulations providing three distinct releases
JP3015105B2 (en) Powder coated oral dosage form
US4309406A (en) Sustained release pharmaceutical compositions
US4673564A (en) Sustained release pharmaceutical composition of solid medical material
US4904476A (en) Formulations providing three distinct releases
US5370880A (en) Pharmaceutical formulations containing acrivastine
ES2606463T3 (en) Combination of levodopa / carbidopa immediate release and controlled release dosage forms
JP5610663B2 (en) Trospium once a day dosage form
GB2025227A (en) Pharmaceutical preparations in retard form
SI9420040A (en) Extended release, film coated tablet of astemizole and pseudoephedrine
PL189016B1 (en) Orally administered formulation of retarded instantaneous release and method of obtaining same
EP0605174A1 (en) Delayed, Sustained-release pharmaceutical preparation
SK78694A3 (en) Solid medicamentous form with regulated release of drug and method of its preparing
MXPA03009588A (en) A novel coating for a sustained release pharmaceutical composition.
IE832358L (en) Compositions comprising a pyrimidopyrimidine derivative
AU611637B2 (en) Sustained release formulations containing 4-(1-methyl-4- piperidylidene)-4H-benzo(4,5)-cyclohepta(1,2-b)thiophen- 10(9H)-one
WO1997033574A1 (en) Sustained-release metal valproate tablets
GB2038181A (en) Galenical compositions
US4411882A (en) Galenical compositions
KR20000036039A (en) Controlled Release Dosage Form of [R-(Z)]-alpha-(methoxyimino)-alpha-(1-azabicyclo[2.2.2]oct-3-yl)acetonitrile Monohydrochloride
JP2665858B2 (en) Long-acting oxybutynin hydrochloride preparation
RU2359660C2 (en) Pharmaceutical composition containing pyrimidin -a-one derivative, covered with intestine-soluble polymer

Legal Events

Date Code Title Description
PCNP Patent ceased through non-payment of renewal fee